Murdoch University Alumnus
Chen Xiaodong joined Intime Retail (Group) Co., Ltd (1833.HK) in 2007, bringing with him a wealth of experience in finance, asset management and retail business. He has been the company's CEO since 2009, with an overall responsibility for Intime Retail's financial management and business operations. The company has more than 8,000 employees and 46 stores.In 2015, online business giant Alibaba became Intime Retail’s largest shareholder.
Under Chen’s leadership, Intime Retail turned to innovation and a more Internet-minded way of doing business, and as a result, total sales growth has been at the forefront of the industry for years. A management expert, Chen has steered the company in such a way that the per capita income and per capita taxes that Intime Retail created are much higher than others in Chinese market. He introduced the first 30-day, no-hassle return policy in Chinese retail, including refunds and returns, in line with the company’s ‘customer first’ policy. Within the company, Chen encourages a united, loving corporate culture that emphasises making customers and employees happy.
With Chen at the helm, Intime Retail has received numerous honours, including China Top 500 Private Enterprises, China' Top 100 Private Service Enterprises, National Retail eEnterprise With Five-star Service Quality, and China's 2015 Best innovation Practices Award in the o2o Retailing Channel. The instant successes of Miaojie, Miaohuo, Miaoke, Choice, JiHood and Yintai (Intime-online) prove that Chen’s spirit of innovation has its rewards.
Chen’s focus is not just on business; he also has a philanthropic side, focusing specifically on poverty reduction. In 2011, he stressed that Intime Retail should do more to help society beyond the company’s work objectives. During the Ya’an earthquake in China in 2013, Intime Retail stores across the country were engaged in a donation drive organised by Chen, who also set up a volunteer group to help the disaster area.
Monash University Alumnus
Thomas Ko is an internationally recognised expert in oral biological drug delivery and sports medicine. He has unique expertise in stabilising biological molecules into tablet forms that are stable at room temperature and deliver the active material through the sublingual lymphatic system to the body without injections.
Ko migrated to Australia in 1960 and established his own pharmaceutical company in Australia in 1971. Since then, he has developed more than 200 commercial products in his 40-year pharmaceutical career. The products he has developed are mainly for human and animal health, in addition to products for household and military use.
Ko has been the Founder and Managing Director of Vitapharm Pharmaceutical Pty. Ltd. In Melbourne, Australia, from its inception in 1971 until 2001. The company specialised in human and veterinary pharmaceutical products, and in 2002 it won the Australian Business Award. That same year the company was publicly listed as Vital Biotech Holdings Limited on the GEM board of the Hong Kong Stock Exchange in 2002, and on the Main Board of the HKSE in 2003.
In October 2004, Ko retired from Vital Biotech as Founder, CEO and Chairman. He privatised the Protein Stabilisation and Delivery Technology from Vital Biotech Holdings Ltd. in Hong Kong and established Vitapharm Technology Development Co. in mainland China in 2006.
In 2008, he was appointed Sports Medicine and Nutrition consultantto the Chinese Ministry of Sports during the Beijing Olympics in 2008. Ko and his products played a major role in assisting 125 Chinese mountaineers to relay the Olympic torch to the peak of Mount Everest in 2008, and a major medical role in the Chinese Women's Hockey Team, which won the first Olympic Medal (Silver) for China that year.
In 2012, Ko established BioLingus Technology Development (Hong Kong)P.L., which specialises in the oral delivery of peptides such as insulin and proteins such as interleukines in sublingual immunotherapies. In 2015, Ko became the founder and a major shareholder in BioLingus GMBH (Switzerland). The company was awarded the Most Innovative Biotech Company 2016 award from European CEO Magazine for its non-invasive sublingual drug delivery technology. The award will be presented at the World Economic Forum in Davos, Switzerland in 2017.
Macquarie University Alumnus
Hong Kong based
JC Liu is a Chinese business leader with 30 years of experience in government and business. He has a proven track record in building up business and managing capital market transactions such as IPOs, cross-border mergers and acquisitions. Prior to moving into the private sector, he served the Chinese government in mainland China and in Hong Kong for 16 years and directly participated in the takeover of Hong Kong as a Division Chief in the Foreign Affairs Department of Xinhua News Agency in the lead-up to 1997.
Liu graduated from Macquarie University with Master’s Degrees in Management and Business Administration. In 2001, he was awarded the Hong Kong Management Association (HKMA) Award Strategic Management Prize.
In the last decade, JC has accumulated an impressive list of achievements such as successfully managing the IPO of Dynasty Fine Wines Group Limited and the HKD11 billion acquisition deal of Tianjin Port Development Holdings Limited, the operator of the world's 4th largest port by volume. His latest venture, Richfields Capital, assists Chinese SMEs to access the capital market and supports overseas corporations in developing the Chinese market and investment. He is currently setting up two major master franchise networks respectively for a leading Italian retail group and a French artisanal sorbet brand with an 80-year history. JC is also a member of the Chaine des Rotisseurs, one of the oldest international gastronomic societies in the world. Richfields Capital is a member of the Hong Kong Venture Capital and Private Equity Association.
JC gives his time freely to Macquarie University. He has been part of the Macquarie Graduate School of Management’s (MGSM) international marketing campaign and has served as the Occasional Speaker at the Macquarie University Graduation in Hong Kong, inspiring over 250 graduates and guests with his career journey. He is very keen to support the network and connecting people to support their own journeys. JC also donates to the scholarship fund of Macquarie University to help students in Hong Kong and mainland China to study at Macquarie.
The University of Newcastle Alumnus
A worldleader in his field, Professor Xiaofei Zhang is a Professor in Epidemiology and Biostatistics and Director of Clinical Epidemiology and Biostatistics at Tsinghua Beijing Changgung Hospital, Medical Center of Tsinghua University. Professor Zhang’s area of expertise is in non-communicable diseases (NCD).
Professor Zhang’s medical career began in 1981, when he pursued a Bachelor of Medicine degree at Jilin University in Changchun, China. He went on to obtain a Master’s degree in Medical Science and Epidemiology in Beijing. He graduated from the University of Newcastle with a PhD in Clinical Epidemiology and Community Health in 2006.
Professor Zhang is a prolific researcher with more than 40 publications in national and international journals and books. He has investigated a wide range of areas including: epidemic trends, risk factors and the prevention of cardiovascular disease in China; work- and disability-related injuries, particularly in the US; risk factors for stroke; factors influencing hypertension; and AIDS.
In 2006, Professor Zhang was involved in a National Institutes of Health project R01 for the US National Health Interview Study, focusing on work-related injuries among foreign and US-born employees. In 2008, he was offered a position as Senior Research Fellow in Epidemiology at the University of Sydney in Australia. There he worked on an initiative for tobacco control in China and also conducted salt modeling work for predicting cardiovascular disease in Australians.
From 2009-12 he was a Professor in Epidemiology and Public Health at the National Center for Chronic and Non-Communicable Disease Control and Prevention in China. Professor Zhang was involved in high-level research projects such as developing a program to prevent non-communicable diseases in China. His public health research and practise has helped inform policy decisions and evidence-based medicine by identifying risk factors for disease and targets for preventive medicine.
Professor Zhang is a member of the America Heart Association; American Association of Public Health; Australian Institute of Medical Scientists; Chinese Heart Association; Chinese Association on Tobacco Control; and Chinese Association of Heart Rehabilitation and Control; and the Specialty Committee of Clinical Scientific Research Statistics of World Federation of Chinese Medicine Societies.
He is a regular presenter at international conferences and a listed reviewer on a number of national and international journals. He is also listed as a respected reviewer of several medical journals including Circulation, Stroke (American Heart Association and American Stroke Association), Atherosclerosis (European Heart Association), Journal of Occupational and Environmental Medicine, Chinese Journal of Preventive Medicine, Chinese Journal of Hypertension, Chinese Journal of Cardiology, and Chinese Journal of Internal Medicine.
The University of Newcastle is very proud of Professor Zhang’s internationally recognised achievements within the field of epidemiology, and his contribution to public health in China, Australia and the US. We are honoured to nominate Professor Zhang for the Australia China Alumni Award for Research and Innovation.
Monash University/RMIT University Alumnus
Robert Zhu has rich experience in global security business management. As Chairman and CEO of ZNV Technology, one of the leading electronic security and power and environment monitoring companies in China, he oversees all company operations. Zhu has consistently delivered profitable growth for the company, and he was given progressively increasing responsibilities to rise to where he is today.
Prior to joining ZNV, Zhu was the Vice President and SA (South Asia) General Manager of ABB Group, where he worked for 10 years. From early 2008 to 2013, he worked as the Asia Pacific President and China President at Tyco, one of the largest security enterprises in the world. Under his leadership, Asia Pacific business grew strongly. In the Chinese market, Zhu led his team in making great improvements, from selling only products to providing integrated security solutions and alarm operation services.
Having lived and worked in China, Australia, Malaysia and Singapore, Robert has developed adaptable management skills that he has successfully applied in various business and industry environments. He was awarded as one of the most innovative entrepreneurs of the year in China in May 2016, one of the highest awards entrepreneurs can receive from the Chinese government.
Zhu holds a Bachelor’s Degree from North China Electric Power University. In the late 1980s he studiedat RMIT University in Australia, graduating with a Master’sDegree in Electronic Engineering. In 2003 he attained his MBA in Business Strategy and Global Business from Monash University.
RMIT University Alumnus
Under Richard Tan's leadership, Shui On Group has become a serious player in the technology investment space. Mr Tan holds three main portfolios under the parent group，Shui On Development Holdings Ltd.
First being the Managing Partner of Shanghai RuiChuang Fund Management PvtLtd. There, Tan is a managing partner in-charge of a US$6 million fund to invest in seed- and angel-stage technology ventures. He successfully raised the fund by bringing in Prosperity Investment (China's largest private sector FoF), Citic Capitals, etc. He mapped out the investment strategy and invested in 48 ventures; two of which have yielded more than 75 times the return. His strong business acumen and amicable personality won the support of other prominent and influential investors to join the fund, while others formed alliances for co-investment. His effective portfolio management also yielded a highly respectable 60% IRR for the fund. With a strong track record, Mr Tan has obtained his Board's approval, and is in the midst of setting up a USD30mn fund.
Second, as Chief Executive of ChuangPai Investment Consulting Company, Tan is in charge of developing an incubation platform called InnoSpace. He successfully built up a competent team and an effective market oriented platform. InnoSpace's international acceleration programme has also become one of the most successful in China, with many organisation and overseas government agencies engaging InnoSpace to help accelerate their start-ups. Under his leadership, InnoSpace has become one of China's most influential accelerator. Recently, Shanghai Government also bestowed the status of "best accelerator in Shanghai to InnoSpace. He recently launched InnoSpace+, a flagship project for the Group.
Third, as Chief Executive, Tan is in charge of transforming ShuiOn's Knowledge & Innovation Community (KIC) into the Silicon Valley of China. He successfully built up a competent team and robust ecosystem, with a clear five-year plan to produce 10 big companies in China by 2017.
Since his involvement three years ago, KIC is transformed and is now touted as the innovation hub for South China. Its robust ecosystem effectively produces some of the world's largest industry players such as eBao Tech; the world's 3rd largest insurance software company. KIC boasts more than 700 companies, hiring 25,000 talented workforce.
Finally, as general manager of Shui On Land Ltd, Tan is in charge of developing and managing close to 2 million square meters of Software Park, as part of the overall 3.6 million square metre Dalian Tiandi project. Tan successfully built up a critical workforce of 15,000 with key companies like IBM, New York listed Ambow, and others in just five years. He developed and implemented the Group's International Strategic Partnership initiatives and formed strategic and investment partnerships with Mitsui Fudosan. Attracted California Trade & Investment Office, and USA Korea's Hanwha Group.